RecruitingNot ApplicableNCT07226674

Microbiota Mediated Flavonoid Metabolites for Cognitive Health

MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health


Sponsor

University of Ulster

Enrollment

100 participants

Start Date

Nov 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Globally, populations are ageing increasing the prevalence of Alzheimer's disease (AD), due to lack of effective treatments. The traditional Mediterranean diet, rich in fibre and polyphenols (PPs) can help prevent or delay cognitive dysfunction and preserve healthy brain structure and function. Cognitive decline is inversely associated with higher PP intakes (\>421mg/day) i.e., total flavonoids, flavan-3-ols and flavonoid oligomers. The positive brain effects of flavonoid intake are likely mediated in part by gut microbial PP metabolites, consistent with the emerging role of the brain-gut microbiome (BGM) system in neurodegeneration. Our preliminary data indicate that circulating phenyl-γ-valerolactones (PVL), neuroprotective compounds exclusively produced by gut microbiota from flavan-3-ol rich foods18 are associated with delaying cognitive dysfunction. Intake of PPs change gut microbial composition and function, altering the physiology of the host's secondary bile acid (BA) pool through modulation of bacterial 7α-dehydroxylation of de-conjugated primary BAs into secondary BAs. This is noteworthy as 7α-dehydroxylation of BAs does not happen in the brain and because gut microbial BA metabolites have regulatory and signalling functions in the brain. The ratio between certain primary and secondary BAs is also dysregulated in AD with significantly lower serum concentrations of cholic acid (a primary BA) and increased levels of deoxycholic acid (a bacterially produced secondary BA). The increased ratio of cholic acid to deoxycholic acid is correlated with cognitive decline. Increased levels of tyrosine, tryptophan, purine, and tocopherol have also been identified in postmortem AD brains. However, specific pathways and mechanisms underlying these associations are unclear. In this multi-PI application by leaders in the field of BGM interactions, we leverage the collectively (NIH, HSC, SFI) funded Tripartite US-Ireland R\&D Partnership Program to determine the mechanisms involved in PP intake on maintaining healthier cognitive and brain function, as mediated by gut microbiota metabolites of PP and BAs in 50+ year old elderly with enhanced AD risk.


Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether special plant compounds called flavonoids — processed by gut bacteria — can support brain health and reduce the risk of Alzheimer's disease in older adults with risk factors. Participants will take a flavonoid supplement and have their cognition monitored. **You may be eligible if...** - You are 50 years old or older - You are overweight (BMI 25 or higher) - A close family member (parent or sibling) has been diagnosed with Alzheimer's disease - You typically eat a Western-style diet (high in processed foods and animal products) **You may NOT be eligible if...** - You already show signs of cognitive impairment or dementia - You have a psychiatric condition like psychosis - You are currently being treated for dementia - You have had a stroke, substance abuse history, or smoke heavily - You have taken probiotics or antibiotics in the past month - You follow a vegetarian, vegan, or other special diet - You are pregnant, breastfeeding, or weigh more than 400 lbs - You are allergic to any ingredients in the study products Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTPolyphenol Supplement

Juice Plus Essentials, Berry Blend Capsules

DIETARY_SUPPLEMENTPlacebo Supplement

Micronutrient matched placebo


Locations(1)

Ulster University, Human Intervention Studies Unit

Coleraine, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226674


Related Trials